Best Companies Group and Seattle Business Magazine again honored the training and business coaching provider as an outstanding place to work for company culture and employee retention SEATTLE, Jan. 9, ...

BDR Pharmaceutical has launched generic antifungal drug Zisavel (isavuconazole) for the treatment of infections like invasive aspergillosis and mucormycosis. The drug is priced at ₹7,992 (for seven ...

IT and telecoms specialist BDR Group has added cybersecurity and cloud services provider Eloquent Technologies to its growing list of M&A deals. The acquisition marks another significant milestone in ...

Mumbai: BDR Pharmaceutical announced the launch of the first-of-its-kind generic drug, Zisavel Capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of ...

Apalutamide shows a significant decrease in the risk of disease progression and reduces the risk of mortality in metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant ...

A consortium led by private equity firm Multiples Alternate Asset Management Pvt. Ltd has bought 9.3% stake in Mumbai-based BDR Pharmaceuticals International for Rs 685 crore ( around $88 million).

The pandemic has been challenging, but it’s also taught pharma companies a few things, says Raheel Shah, next-generation of the promoter family, at the ₹1,500-crore BDR Group. Citing the many ...

The marketing authorisations would help Venus Remedies further strengthen its oncology portfolio and improve its presence in the oncology space. (File) BDR Pharmaceutical on Tuesday announced that it ...

NEW DELHI: Private equity firm Multiples Alternate Asset Management Pvt. Ltd-led consortium has invested ₹685 crore, or around $88 million, in drugmaker BDR Pharmaceuticals International for a 9.3% ...